CytomX Therapeutics, Inc. Logo

CytomX Announces Upcoming Trials in Progress Poster Presentations at European Society for Medical Oncology Annual Meeting

September 8, 2017

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced upcoming Trials inProgress poster presentations for its two lead product candidates, CX-072, a PD-L1 targeting Probody therapeutic and CX-2009, a Probody-drug conjugate targeting CD166, at the European Society for Medical Oncology Annual Meeting from September 8-12 in Madrid, Spain.

Abstract Information:

Title:	The First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial to Assess the Antitumor Activity and Tolerability of the Probody Therapeutic CX-072 as Monotherapy and in Combination With Ipilimumab or Vemurafenib in Solid Advanced Tumors and Lymphomas
Author:	Valentina Boni, M.D., Ph.D., START Madrid-CIOCC, Madrid, Spain
Date:	Monday, September 11, 2017
Time:	1:15 p.m. – 2:15 p.m.
Location:	Hall 8
Abstract:	423TiP

About the PROCLAIM-CX-072 Trial:

The PROCLAIM-CX-072 (**PRO**body **CL**inical **A**ssessment **I**n **M**an) study is designed to evaluate tolerability, and preliminary antitumor activity and translational biomarkers of multiple doses of CX-072 as monotherapy or as combination therapy with ipilimumab or vemurafenib in patients with advanced, unresectable solid tumors or lymphoma. This first-in-human, open-label, multicenter, dose-escalation, phase 1/2 study of CX-072 includes 4 dose-escalation groups (monotherapy, Part A; 2 ipilimumab combination schedules, Parts B1 and B2; vemurafenib combination, Part C), a stage testing biomarkers and efficacy in PD-L1+ tumors (Part A2), and a dose-expansion phase (Part D).

Abstract Information:

Title:	PROCLAIM-CX-2009: A First-in-Human Trial to Evaluate CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors
Author:	Javier Garcia-Corbacho M.D., Hospital Clinic Barcelona, Barcelona, Spain
Date:	Monday, September 11, 2017
Time:	1:15 p.m. – 2:15 p.m.
Location:	Hall 8
Abstract:	422TiP

About the PROCLAIM-CX-2009 Trial:

The objectives of the ongoing PROCLAIM-CX-2009 (**PRO**body **CL**inical **A**ssessment **I**n **M**an) module are to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose-limiting toxicities, and preliminary antitumor activity of CX-2009 as monotherapy in the following 7 selected tumor types with high CD166 expression: breast carcinoma, castration-resistant prostate carcinoma (CRPC), cholangiocarcinoma, endometrial carcinoma, epithelial ovarian carcinoma, head and neck squamous cell carcinoma (HNSCC), and non–small cell lung carcinoma (NSCLC).

About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of Probody™ therapeutics. Probody therapeutics exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company's pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1 and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.

Media Contact:
Spectrum
Christine Quern
cquern@spectrumscience.com
202-587-2588

Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973

CytomX Therapeutics Inc.